The first vaccine for the active immunisation of individuals at risk of infection from the Ebola virus is being recommended for use in countries affected by the disease including the Democratic Republic of Congo where a public health emergency has been declared by the World Health Organization.
The vaccine, Ervebo, was reviewed by the European Medicines Agency and given a positive opinion on 17 October. It was developed by Merck & Co.